Sign in
4

Changes in Ownership

Dyne Therapeutics, Inc. Filed Acc 0001193125-25-309636

Chief Commercial Officer sold 144 shares at $20.72 ($2,984)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Friedl-Naderer Johanna Chief Commercial Officer 2025-12-05 Sale 10b5-1 −144 $20.72 $2,984 94,729 D
Open-market sales · 144 sh · avg $20.72 · $2,984
Loading xslF345X05/ownership.xml…